Six Republican Senators ‘Cross Aisle’ To Save Biden’s Pro-Abortion FDA Nominee

Joe Biden’s controversial pick to direct the Food and Drug Administration (FDA) was narrowly confirmed by the Senate on Tuesday despite not having the support of five Democrats. Six Republicans made up the lost ground for Biden by crossing the aisle to vote in favor of the pro-abortion nominee.

The final vote in the Senate was 50-46 to approve Dr. Robert Califf to lead the FDA for a second time. He served previously in the post under Barack Obama from 2016 to 2017.

Sens. Joe Manchin (D-WV), Bernie Sanders (I-VT), Richard Blumenthal (D-CT), Maggie Hassan (D-NH), and Ed Markey (D-MA) all voted against Califf’s nomination. Those Democrats generally stood together in criticism of Califf’s close ties to the pharmaceutical industry and his failed efforts to regulate opioids when previously at the FDA.

Most Senate Republicans opposed Califf because of his long-term efforts to deregulate access to chemical abortion pills. The pills promote easy access to on-demand abortions and carry four times the medical complications that standard surgical abortions do.

Califf’s nomination was rescued by Sens. Mitt Romney (R-UT), Roy Blunt (R-MO), Richard Burr (R-NC), Susan Collins (R-ME), Lisa Murkowski (R-AK), and Pat Toomey (R-PA), who all voted with the remaining Democrat Senators to approve Califf.

During Califf’s first stint as FDA Director, the nation saw a record number of deaths from overdose of prescription opioids. Manchin said he expects problems with opioid deaths to continue during his coming term. He said that Califf “has shown us who he is” and that he has a “complete lack of interest” in the tough decisions an FDA leader must make.

While at the Duke Clinical Research Institute, Califf worked as a paid consultant for several giant drug companies, including Merck, GlaxoSmithKline, Eli Lilly, and Johnson & Johnson. In opposing Califf, Markey said that Califf refused to commit to the reforms of the pharmaceutical industry that are necessary to combat opioid abuse.

Under Califf’s previous directorship, the FDA changed the reporting requirements that apply to providers of chemical abortion pills, allowing them to no more comprehensive report adverse medical events other than deaths.

The Republican Senators who voted for Biden’s pro-abortion nominee must have felt a more vital duty to pharmaceutical giants than the thousands of babies who have been killed through the use of dangerous and readily available abortion pills.